<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916769</url>
  </required_header>
  <id_info>
    <org_study_id>B1871063</org_study_id>
    <secondary_id>2021-000500-38</secondary_id>
    <nct_id>NCT04916769</nct_id>
  </id_info>
  <brief_title>Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, RANDOMIZED, 3-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOAVAILABILITY OF BOSUTINIB ADMINISTERED AS CAPSULE CONTENTS MIXED WITH APPLESAUCE OR YOGURT RELATIVE TO INTACT CAPSULES IN HEALTHY PARTICIPANTS UNDER FED CONDITION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to estimate the relative bioavailability of a single 500 mg dose of&#xD;
      bosutinib when administered as capsule contents mixed with applesauce or yogurt to intact&#xD;
      capsules under fed condition in adult healthy participants. The comparisons will be performed&#xD;
      using the pharmacokinetic parameters that define the rate and extent of absorption, those are&#xD;
      Cmax and AUC. Statistical analyses will be performed comparing these parameters calculated&#xD;
      after administration of a single 500 mg dose with the intact capsule formulation (100 mg x 5)&#xD;
      as the Reference treatment and the capsule contents mixed with applesauce or yogurt (100 mg x&#xD;
      5) as the Test treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Phase 1, open-label, randomized, single dose, 3-period, 6-sequence, crossover study in healthy participants</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)]</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma elimination half-life (t1/2)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Bosutinib capsule contents mixed with applesauce</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosutinib capsule contents mixed with applesauce to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosutinib capsule contents mixed with yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosutinib capsule contents mixed with yogurt to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosutinib intact capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bosutinib intact capsules to healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib capsule</intervention_name>
    <description>500 mg dose of bosutinib capsule contents mixed with applesauce</description>
    <arm_group_label>Bosutinib capsule contents mixed with applesauce</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib capsule</intervention_name>
    <description>500 mg dose of bosutinib capsule contents mixed with yogurt</description>
    <arm_group_label>Bosutinib capsule contents mixed with yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib capsule</intervention_name>
    <description>500 mg dose of intact bosutinib capsules</description>
    <arm_group_label>Bosutinib intact capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female participants of non childbearing potential and/or male participants must be 18&#xD;
             to 54 years of age, inclusive, at the time of signing the informed consent document&#xD;
             (ICD).&#xD;
&#xD;
          -  Capable of giving signed informed consent as described in Appendix 1, which includes&#xD;
             compliance with the requirements and restrictions listed in the ICD and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,&#xD;
             dermatological, or allergic disease.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption.&#xD;
&#xD;
          -  Participants with ANY of the following abnormalities in clinical laboratory tests at&#xD;
             screening, as assessed by the study-specific laboratory and confirmed by a single&#xD;
             repeat test, if deemed necessary:&#xD;
&#xD;
               1. estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology&#xD;
                  Collaboration [CKD-EPI]) &lt; 90 mL/min/1.73 m2;&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level &gt; upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
               3. Serum (total and direct) bilirubin level &gt; ULN; participants with a history of&#xD;
                  Gilbert's syndrome may have direct bilirubin measured and would be eligible for&#xD;
                  this study provided the direct bilirubin level is &lt;= ULN;&#xD;
&#xD;
               4. Amylase and lipase levels &gt; ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-capitale, RÃ©gion DE</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1871063</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>bosutinib</keyword>
  <keyword>Maximum Observed Plasma Concentration (Cmax)</keyword>
  <keyword>Area Under the Curve (AUC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

